TTRX (TTRX) reported D&A of $14.45K in Q1 2026.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

TTRX TTRX D&A

D&A at other companies

Regeneron PharmaceuticalsREGN

$123.2M-2.9%

Bausch Health CompaniesBHC

$295M-3.3%

PTH

Pelthos Therapeutics Inc.PTHS

$469K—

Celldex TherapeuticsCLDX

$854K-1.5%

Kymera TherapeuticsKYMR

$2.02M-1.3%

Tarsus Pharmaceuticals, Inc.TARS

$197K-10.5%

Other financials

Income statement

See full

Operating income-$1.2M-224%

Net income-$971.0K-196%

EPS (diluted)-$0.03-200%

Balance sheet

See full

Cash & equivalents$11.2M+613%

Total debt$6.0M—

Total equity$6.1M+647%

Total assets$18.6M—

Cash flow

See full

Operating cash flow-$1.6M-448%

Valuation

See full

Market cap$217.45M-17.7%

Enterprise value$212.24M—

Returns & leverage

See full

Return on equity-118.8%—

Debt / equity1×—

Current ratio2.2×—

Where this comes from

Reported directly by TTRX in its filing.

Tagged under the XBRL concept us-gaap:AdjustmentForAmortization.

The official record: TTRX’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about TTRX's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is TTRX's D&A?: TTRX (TTRX) reported D&A of $14.45K in Q1 2026.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.